Identification of Therapeutic Targets in Metastatic Gastric Cancer

April 22, 2026 updated by: CHAN SHANNON MELISSA, Chinese University of Hong Kong

Identification of Novel Therapeutic Targets in Gastric Cancer With Lymph Node or Distant Metastasis: An Explorative Study

This is a pilot study aiming at identifying novel therapeutic molecular targets in patients with gastric cancer with lymph nodes or distant metastasis. All patients who are diagnosed with gastric cancer with metastases in the Prince of Wales Hospital will be screened for eligibility.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Patients admitted into PWH

Description

Inclusion Criteria:

  1. Patients age >= 18, <= 80 years old
  2. Performance status (WHO) <=2
  3. Gastric adenocarcinoma with lymph node metastasis or distant metastasis such as liver metastases, lung metastases, bone metastases, peritoneum metastases
  4. Patients with isolated ovarian metastasis could be included
  5. Patients who will be undergoing neoadjuvant chemotherapy/ target therapy/ immunotherapy or palliative chemotherapy/ target therapy/ immunotherapy
  6. Ability to give written consent before the commencement of treatment

Exclusion Criteria:

  1. Patient who will not be undergoing neoadjuvant chemotherapy/ target therapy/ immunotherapy or palliative chemotherapy/ target therapy/ immunotherapy
  2. Pregnancy or breastfeeding
  3. Patients with irreversible coagulation disorders

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Biobank construction
Time Frame: Collect at baseline(pre-treatment) and/or during interval surgery if clinically indicated and/or after completing all systemic and surgical treatment if patient required an endoscopy or laparoscopy due to clinical need only.
Recruit patients and collect the required biological samples (i.e. tumor tissues, blood and ascites samples) for biobank construction.
Collect at baseline(pre-treatment) and/or during interval surgery if clinically indicated and/or after completing all systemic and surgical treatment if patient required an endoscopy or laparoscopy due to clinical need only.
Detection of noval therapeutic targets for treating gastric cancer cancer with metastases.
Time Frame: Collect at baseline(pre-treatment) and/or during interval surgery if clinically indicated and/or after completing all systemic and surgical treatment if patient required an endoscopy or laparoscopy due to clinical need only.
Biological samples (i.e. tissue, blood and ascites samples) collected from enrolled patients will be used in genome and transcriptome analysis using next generation sequencing, DNA mutation detection using digital PCR and mass spectrometry-based proteomic.
Collect at baseline(pre-treatment) and/or during interval surgery if clinically indicated and/or after completing all systemic and surgical treatment if patient required an endoscopy or laparoscopy due to clinical need only.
Organoid culture for drug sensitivity assay
Time Frame: Collect at baseline(pre-treatment) and/or during interval surgery if clinically indicated and/or after completing all systemic and surgical treatment if patient required an endoscopy or laparoscopy due to clinical need only.
Gastric tumor tissues are collected from enrolled patients to establish patient-derived organoids and subject to drug sensitivity assay. The choice of drugs will depend on the molecular analysis results and will be advised by oncologists.
Collect at baseline(pre-treatment) and/or during interval surgery if clinically indicated and/or after completing all systemic and surgical treatment if patient required an endoscopy or laparoscopy due to clinical need only.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical Outcome - Overall survival
Time Frame: through study completion, an average of 5 year
Patients' overall survival will also be recorded.
through study completion, an average of 5 year
Clinical Outcome - Progression-free survival
Time Frame: through study completion, an average of 5 year
Patients' progression-free survival will also be recorded.
through study completion, an average of 5 year
Clinical Outcome - Karnofsky Score
Time Frame: At baseline measurement
Karnofsky Score for measuring quality of life will be recorded
At baseline measurement
Clinical Outcome - Time point of metastasis
Time Frame: Recruitment till death or 5 year
Patients' time point of metastasis, whether it is synchronous or metachronous will be recorded
Recruitment till death or 5 year
Clinical Outcome - Number of previous chemotherapy/ target therapy/ immunotherapy
Time Frame: Measured and asked at baseline
Number of previous chemotherapy/ target therapy/ immunotherapy received by the patients will be recorded
Measured and asked at baseline
Clinical Outcome - Presence of ascites
Time Frame: Recruitment till death or 5 year
Presence of ascites on recruited patients will be recorded
Recruitment till death or 5 year
Clinical Outcome - Cancer Restaging
Time Frame: Post-treatment till death or 5 year
Stage of cancer will be recorded and determined with CT/PETCT scan
Post-treatment till death or 5 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Chinese University of Hong Kong

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 15, 2023

Primary Completion (Estimated)

April 1, 2033

Study Completion (Estimated)

October 1, 2033

Study Registration Dates

First Submitted

August 10, 2023

First Submitted That Met QC Criteria

April 22, 2026

First Posted (Actual)

April 24, 2026

Study Record Updates

Last Update Posted (Actual)

April 24, 2026

Last Update Submitted That Met QC Criteria

April 22, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2023.117

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stomach Neoplasms, Benign

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe